PONTE VEDRA, Fla., Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, will participate in the following upcoming conferences that will be available to investors by we ...

财务信息发布 - 公司在2024年6月30日的第二季度财报电话会议上发布了财务信息[11] - 公司在2024年8月7日发布了第二季度财报新闻稿[11] 公司概况 - 公司在纳斯达克资本市场上市，股票代码为CVKD[8] - 公司是一家新兴成长型公司[9] 会计准则遵守 - 公司未选择采用延长过渡期来遵守新的或经修订的财务会计准则[10]

PONTE VEDRA, Fla., Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly Report on Form 10-Q ...

新药研发 - 公司正在开发一种新一代的维生素K拮抗剂(VKA)口服可逆性抗凝血剂tecarfarin，用于预防罕见心血管疾病患者由于血栓而导致的心脏病发作、中风和死亡[117] - tecarfarin已在11项临床试验中评估,超过1000名受试者参与,269名患者接受了至少6个月的治疗,129名患者接受了1年以上的治疗,总体耐受性良好[118] - tecarfarin采用不同的代谢途径,不依赖于最常用的CYP450代谢通路,可能有助于避免由于多药物相互作用或肾功能障碍导致的药物积累和毒性[119] 融资情况 - 公司于2023年1月完成首次公开发行,筹集资金7000万美元[122] - 公司于2023年7月完成私募配售,筹集资金750万美元[123][124] - 截至2024年6月30日,公司现金及现金等价物约500万美元,无债务[136] - 公司预计未来12个月内现有现金不足以支持运营,需要通过合作和股权/债务融资来筹集更多资金[137] - 公司在截至2024年6月30日的六个月内融资活动提供现金298美元[141] - 公司在截至2023年6月30日的六个月内融资活动提供现金540.86万美元[142] 财务状况 - 公司在截至2024年6月30日的六个月内经营活动使用现金336.56万美元[139] - 公司在截至2023年6月30日的六个月内经营活动使用现金220.81万美元[140] - 公司需要做出重大估计和假设,如金融工具公允价值、股票激励公允价值、递延税资产和估值准备、所得税不确定性以及某些应计费用[143] - 公司评估所有协议以确定是否包含衍生工具或嵌入式衍生工具,并将可赎回特征作为负债按公允价值入账[144] - 公司采用黑-斯科尔斯期权定价模型估算股票激励的公允价值,并采用直线法确认股份支付费用[145] - 公司在报告期内没有任何资产负债表外安排[146] - 公司被界定为较小报告公司,无需提供市场风险的量化和定性披露[147]

PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it has been in discussions with Abbott (NYSE: ABT) about Cadrenal's planned p ...

PONTE VEDRA, Fla., July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the next Emerging Growth Conference, a virtual forum for institutional and retai ...

PONTE VEDRA, Fla., June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the Emerging Growth Conference on June 12, 2024.Management will deliver a webcas ...

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomes PONTE VEDRA, Fla., June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible ant ...

PONTE VEDRA, Fla., May 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Recent Highlights In April 2024, recei ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 88-0860746 (State or other jurisdiction o ...